HomeCompareGLYC vs PM

GLYC vs PM: Dividend Comparison 2026

GLYC yields 12.73% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $3.3K in total portfolio value· pulled ahead in Year 9
10 years
GLYC
GLYC
● Live price
12.73%
Share price
$15.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.3K
Annual income
$2,813.53
Full GLYC calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — GLYC vs PM

📍 PM pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLYCPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLYC + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLYC pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLYC
Annual income on $10K today (after 15% tax)
$1,082.46/yr
After 10yr DRIP, annual income (after tax)
$2,391.50/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, GLYC beats the other by $273.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLYC + PM for your $10,000?

GLYC: 50%PM: 50%
100% PM50/50100% GLYC
Portfolio after 10yr
$47.9K
Annual income
$2,652.77/yr
Blended yield
5.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

GLYC
Analyst Ratings
8
Buy
5
Hold
Consensus: Buy
Altman Z
13.9
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLYC buys
0
PM buys
0
No recent congressional trades found for GLYC or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLYCPM
Forward yield12.73%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$46.3K$49.6K
Annual income after 10y$2,813.53$2,492.02
Total dividends collected$20.2K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: GLYC vs PM ($10,000, DRIP)

YearGLYC PortfolioGLYC Income/yrPM PortfolioPM Income/yrGap
1$11,973$1,273.48$11,648$408.29+$325.00GLYC
2$14,237$1,425.05$13,589$495.90+$648.00GLYC
3$16,817$1,583.55$15,877$603.21+$940.00GLYC
4$19,742$1,748.17$18,580$734.88+$1.2KGLYC
5$23,042$1,918.01$21,781$896.75+$1.3KGLYC
6$26,747$2,092.16$25,578$1,096.12+$1.2KGLYC
7$30,889$2,269.70$30,092$1,342.17+$797.00GLYC
8$35,501$2,449.70$35,470$1,646.46+$31.00GLYC
9← crossover$40,617$2,631.26$41,892$2,023.58$1.3KPM
10$46,274$2,813.53$49,578$2,492.02$3.3KPM

GLYC vs PM: Complete Analysis 2026

GLYCStock

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Full GLYC Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this GLYC vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLYC vs SCHDGLYC vs JEPIGLYC vs OGLYC vs KOGLYC vs MAINGLYC vs MOGLYC vs BTIGLYC vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.